RGT Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.22 |
| 52 Week High | AU$4.08 |
| 52 Week Low | AU$0.13 |
| Beta | 0.97 |
| 1 Month Change | 0% |
| 3 Month Change | 10.00% |
| 1 Year Change | -94.50% |
| 3 Year Change | -99.25% |
| 5 Year Change | n/a |
| Change since IPO | -99.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGT | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.8% | -0.9% | 1.0% |
| 1Y | -94.5% | 7.4% | 6.7% |
Return vs Industry: RGT underperformed the UK Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: RGT underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| RGT volatility | |
|---|---|
| RGT Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: RGT has not had significant price volatility in the past 3 months.
Volatility Over Time: RGT's weekly volatility has decreased from 17% to 7% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | mgcpharma.com.au |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| RGT fundamental statistics | |
|---|---|
| Market cap | UK£8.95m |
| Earnings (TTM) | -UK£8.97m |
| Revenue (TTM) | UK£698.13k |
12.8x
P/S Ratio-1.0x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGT income statement (TTM) | |
|---|---|
| Revenue | AU$1.32m |
| Cost of Revenue | AU$1.20m |
| Gross Profit | AU$125.39k |
| Other Expenses | AU$17.14m |
| Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 9.47% |
| Net Profit Margin | -1,284.89% |
| Debt/Equity Ratio | 1,366.5% |
How did RGT perform over the long term?
See historical performance and comparison